A detailed history of Financial Gravity Asset Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Financial Gravity Asset Management, Inc. holds 7 shares of VRTX stock, worth $3,291. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7
Previous 12 41.67%
Holding current value
$3,291
Previous $5.13 Million 42.82%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Jun 26, 2024

SELL
$407.69 - $446.08 $2,038 - $2,230
-5 Reduced 41.67%
7 $2.93 Million
Q1 2024

May 13, 2024

BUY
$407.69 - $446.08 $8,561 - $9,367
21 Added 190.91%
32 $13.4 Million
Q4 2023

Jun 26, 2024

SELL
$343.0 - $410.68 $6,860 - $8,213
-20 Reduced 62.5%
12 $5.13 Million
Q3 2023

Nov 15, 2023

SELL
$338.18 - $362.46 $115,319 - $123,598
-341 Reduced 96.88%
11 $3,000
Q2 2023

Aug 08, 2023

BUY
$314.42 - $351.91 $11,633 - $13,020
37 Added 11.75%
352 $4.57 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $7,363 - $8,400
26 Added 9.0%
315 $4.61 Million
Q4 2022

Feb 15, 2023

SELL
$285.76 - $321.48 $2.24 Million - $2.52 Million
-7,831 Reduced 96.44%
289 $4.03 Million
Q3 2022

Nov 03, 2022

SELL
$273.83 - $305.53 $93,102 - $103,880
-340 Reduced 4.02%
8,120 $4.45 Million
Q2 2022

Aug 05, 2022

BUY
$234.96 - $292.55 $148,024 - $184,306
630 Added 8.05%
8,460 $4.6 Million
Q1 2022

May 13, 2022

BUY
$221.42 - $260.97 $1.1 Million - $1.3 Million
4,970 Added 173.78%
7,830 $4.83 Million
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $505,009 - $637,502
2,853 Added 40757.14%
2,860 $1.62 Million
Q2 2021

Aug 11, 2021

SELL
$187.49 - $221.1 $749 - $884
-4 Reduced 36.36%
7 $202,000
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $6,831 - $7,963
-33 Reduced 75.0%
11 $2.37 Million
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $9,108 - $12,147
44 New
44 $10,000
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $66,967 - $87,852
-297 Closed
0 $0
Q1 2020

May 12, 2020

SELL
$199.77 - $247.81 $41,152 - $51,048
-206 Reduced 40.95%
297 $70,000
Q4 2019

Feb 28, 2020

SELL
$166.71 - $223.91 $41,844 - $56,201
-251 Reduced 33.29%
503 $219,000
Q3 2019

Oct 15, 2019

SELL
$166.23 - $187.09 $27,760 - $31,244
-167 Reduced 18.13%
754 $128,000
Q2 2019

Jul 26, 2019

SELL
$164.61 - $190.37 $32,428 - $37,502
-197 Reduced 17.62%
921 $169,000
Q1 2019

Apr 19, 2019

SELL
$163.73 - $194.7 $35,365 - $42,055
-216 Reduced 16.19%
1,118 $208,000
Q3 2018

Oct 31, 2018

BUY
$167.73 - $192.74 $35,894 - $41,246
214 Added 19.11%
1,334 $227,000
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $13,989 - $16,316
-96 Reduced 7.89%
1,120 $196,000
Q1 2018

May 23, 2018

BUY
$151.6 - $177.13 $184,345 - $215,390
1,216 New
1,216 $182,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $121B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Financial Gravity Asset Management, Inc. Portfolio

Follow Financial Gravity Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.